FDA says GSK-Vir’s sotrovimab no longer authorized to treat COVID in U.S

2022.04.05 21:17

FILE PHOTO: A view shows GlaxoSmithKline headquarters in London, Britain, January 17, 2022.REUTERS/Hannah McKay

(Reuters) – The U.S. health regulator said on Tuesday GlaxoSmithKline (NYSE:GSK) and Vir Biotechnology (NASDAQ:VIR)’s drug sotrovimab was no longer authorized to treat COVID-19 in the U.S. due to an increase in the proportion of cases caused by the Omicron BA.2 sub-variant.

Source